Condition: Gastric or Gastroesophageal Junction Adenocarcinoma · Sponsor: Qilu Pharmaceutical Co., Ltd.
This study is a randomized, open, multicenter phase III clinical study designed to compare the efficacy and safety of QLS31905 injection combined with CAPOX versus sintilimab combined with CAPOX in the first-line treatment of CLDN18.2 positive, PD-L1 CPS \< 5 unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
This description comes directly from the study's public registry record.
Lin Shen, PhD · 010-88196358 · doctorshenlin@sina.cn
Always discuss trial participation with your own doctor first.
| Locations not yet listed on the registry record. |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07716449